Kornimate/medical-research-clean huggingface dataset:
master study of the acticor/rivacor icds/crt-ds and the plexa promri s dx lead

Conditions: Heart Failure; Tachyarrhythmia

Summary: post-market clinical follow-up of the new cor family icds/crt-ds (acticor, rivacor) and the new plexa promri s dx right ventricular lead to provide post-market data and supporting evidence for the clinical safety and performance of the devices.


Eligibility criteria:
inclusion criteria: * standard indication for icd or crt-d therapy according to clinical guidelines * planned for de novo implantation of an icd/crt-d, or upgrade/exchange from existing icd/crt-d or pacemaker implant * able to understand the nature of study and to provide written informed consent * willing and able to perform all follow-up visits at the study site * willing and able to use the cardiomessenger and accepts the biotronik home monitoring concept exclusion criteria: * contraindication to icd and crt-d therapy * planned for implantation of a crt-dx system * for vr-t dx devices: permanent atrial tachyarrhythmia * for vr-t dx devices: patients requiring atrial pacing * less than 18 years old * pregnant or breast feeding * participating in another interventional clinical investigation * life-expectancy is less than 12 months * cardiac surgical procedure planned within 12 months after implantation (including interventional procedures like ablation, valve replacement, heart transplant etc.). procedures to occur during or prior to implantation are not exclusionary
genes that affect disease outcome in patients with metastatic colorectal cancer

Conditions: Colorectal Cancer

Summary: rationale: studying samples of blood and tumor tissue in the laboratory from patients with cancer may help doctors learn more about changes that occur in dna and help doctors understand how patients respond to treatment. purpose: this clinical trial is examining genes that affect disease outcome in patients with metastatic colorectal cancer.

objectives: * collect blood samples for dna extraction for genetic studies from patients receiving chemotherapy for metastatic colorectal cancer. * collect detailed clinical, pathological, and chemotherapy data from these patients. * identify genetic factors that relate to treatment response and outcome in these patients. outline: blood samples are collected and relevant genes and regions are amplified by pcr. pcr products are then sequenced or genotyped for known biological markers and single nucleotide polymorphisms. tumor samples from surplus pathology specimens are analyzed for expression of candidate genes and mutation in the candidate genes. clinical and family history data is also collected by questionnaire. projected accrual: a total of 800 patients will be accrued for this study.

Eligibility criteria:
disease characteristics: * diagnosis of metastatic colorectal cancer * currently receiving chemotherapy at weston park hospital patient characteristics: * not specified prior concurrent therapy: * see disease characteristics

Keywords: stage iv colon cancer stage iv rectal cancer
compare the clinical efficacy of prototype toothpastes

Conditions: Dental Plaque

Summary: clinical study to compare the clinical efficacy of toothpastes on dental plaque and gingival inflammation.


Eligibility criteria:
inclusion criteria: * male or female volunteers 18-65 years of age. * good general health. * must sign informed consent form. * minimum of 20 natural uncrowned teeth (excluding third molars) must be present. * no history of allergy to personal care consumer products, or their ingredients, relevant to any ingredient in the test products as determined by the dental/medical professional monitoring the study. exclusion criteria: * subject unable or unwilling to sign the informed consent form. * medical condition which requires pre-medication prior to dental visits/procedures. * moderate or advanced periodontal disease. * 5 or more decayed untreated dental sites at screening. * other disease of the hard or soft oral tissues. * impaired salivary function (e.g. sjogren's syndrome or head and neck irradiation). * use of medications that currently affect salivary flow. * use of antibiotics or antimicrobial drugs within 30 days prior to study visit #1. * pregnant or nursing women. * participation in any other clinical study within 1 week prior to enrollment into this study. * use of tobacco products. * subjects who must receive dental treatment during the study dates. * current use of antibiotics for any purpose. * presence of an orthodontic appliance. * history of allergy to common dentifrice ingredients. * history of allergy to zinc. * immune compromised individuals (hiv, aids, immuno suppressive drug therapy).
nuchal cord detection in sonographic evaluation by a first year resident.

Conditions: Fetal Cord Entanglement

Summary: the investigators aim to prove that minimal sonographic training for nuchal cord detection in an unexperienced first year medical resident is more than enough to detect the phenomenon. patients undergoing elective cesarean section will undergo a routine ultrasound (that is performed to detect the fetal heart rate and the fetal presentation) during which the resident will attempt to detect nuchal cord. the resident will then attend the patient's surgery to verify the findings.

patients undergoing elective cesarean section will undergo a routine ultrasound examination during which fetal heart rate, fetal presentation and nuchal cord presence will be documented. during surgery, after the fetus is delivered, presence or lack of nuchal cord will be documented. the aim of the study is to show that minimal sonographic training may assist even an unexperienced sonographist in detection of such a subtle yet important phenomenon. the study will be performed utilizing the newest resident in the obgyn department.

Eligibility criteria:
inclusion criteria: * any woman undergoing elective cesarean section. exclusion criteria: * none.
clinical evaluation of cordio app in adult adhf patients

Conditions: Congestive Heart Failure

Summary: observational study on adhf patients at one site in israel. after signing informed consent and undergoing screening assessments, eligible patients will record sentences into a smartphone. the app will upload the vocal data to the sponsor's servers for analysis. the patient will record at hospital: admittion, release. before hospital release, if applicable and upon patient agrreement, an app will be installed in a smartphone in order to continue the recording at home.


Eligibility criteria:
inclusion criteria: * diagnosis of adhf (pulmonary congestion) * known diagnosis of hf, with either preserved or reduced lvef. * 18+ years old. * able to understand and provide written informed consent. exclusion criteria: * subjects unable to comply with the daily use of the application due to mental disorders. * gfr \<25 ml/min who are non-responsive to diuretic therapy or who are on chronic renal dialysis. * subjects with congenital heart disease or mechanical right heart valve(s). * airway and lung infection and sepsis * patients with severe alcohol or drug use. * women who are pregnant or lactating.
cedm as a screening tool for breast cancer in higher-risk women: a prospective study

Conditions: Breast Cancer

Summary: to evaluate the effectiveness of contrast-enhanced digital mammography (cedm) in detecting breast cancer in women at higher risk.

the aim of this study was to evaluate the effectiveness of different imaging techniques for detecting breast cancer in women with a higher risk due to personal or family history of the disease.

Eligibility criteria:
inclusion criteria: * women underwent cedm screening exclusion criteria: * incomplete imaging exams

Keywords: breast cancer contrast-enhanced digital mammography
efficacy of resveratrol in depression

Conditions: Depression

Summary: patients with depression (target number - 60) receive resveratrol 500 mg or placebo (1:1) each morning daily for 1 month with primary outcome measures of the score change on depression rating scale hdrs-17 and change in sirt1 activity in the blood measured 4 times over the study period (before, in the middle, after the intervention, and in 2 week follow up).


Eligibility criteria:
inclusion criteria (selectively): * mdd recurrent or with single episode with melancholic features or dysthymia (dsm-5); * current depression. exclusion criteria (selectively): * serious or unstable disease; * antidepressants intake.
phase ii trial of radical pleurectomy with or without intraoperative pdt for malignant pleural mesothelioma

Conditions: Epitheliod Malignant Pleural Mesothelioma

Summary: a randomized phase ii trial to test whether the addition of intraoperative photofrin-mediated photodynamic therapy to radical pleurectomy and post-operative chemo.improves os in the treatment of patients with epithelioid mpm. subjects assigned to the pdt arm will be given the photosensitizer prior to surgery . all subjects will receive maximal surgical debulking. subjects in the pdt arm will receive intraoperative treatment using real-time, isotropic light dosimetry.


Eligibility criteria:
inclusion criteria: * patients with a histologic diagnosis of mpm, epithelioid subtype, who in the opinion of the attending thoracic surgeon can receive a macroscopically complete resection of tumor. * patients must have disease limited to the hemithorax. * patients who have received prior surgery, gene therapy, or combination chemotherapy will be permitted if it has been at least 30 days since the last treatment. * subjects treated with pemetrexed previously will be eligible only if 30 days have elapsed between the last dose of pemetrexed and the date of surgery. * ecog performance status of 0-1. * medical suitability for resection, including documented medical and cardiac clearance. * 18 years of age or older. * patients must sign a document that indicates that they are aware of the investigative nature of the treatment of this protocol, and the potential benefits and risks. patients unwilling or unable due to cognitive impairment to sign informed consent are excluded from the study. exclusion criteria * patients with active invasive cancers, other than mpm, that require additional treatment, except non-melanomatous skin cancer, superficial bladder or cervical cancer, and early-stage prostate cancer * pregnant or lactating patients. * patients who have a history of hiv disease. * patients who have a white count less than 2,500 per cubic mm or platelets less than 100,000/cubic mm. * serum creatinine equal or greater than 2.5 mg/deciliter. * patients who have severe liver disease including cirrhosis, grade iii-iv elevations in liver function studies, or bilirubin in excess of 1.5 mg/deciliter. * patients with porphyria or hypersensitivity to porphyrin or porphyrin-like compounds. * patients who have been treated with pemetrexed if the last dose of pemetrexed is \< 30 days to the date of surgery. * patients that have been treated with prior mantle field radiation. * patients with distant metastatic disease or otherwise not confined to the ipsilateral hemithorax. * subjects who have received more than 2 doses of neo-adjuvant chemotherapy

Keywords: histological diagnosis of mpm epitheliod subtype limited to the hemithorax macroscopically complete resection of the tumor
safety and treatment satisfaction in adults with chronic itp after switching to avatrombopag from eltrombopag or romiplostim

Conditions: Immune Thrombocytopenia

Summary: evaluate the safety and tolerability of avatrombopag given for 90 days after stopping treatment with eltrombopag or romiplostim.

this phase 4, prospective, multi-center, open-label study will evaluate safety, platelet count, and subject reported medication satisfaction in adult subjects with chronic itp after switching to avatrombopag from eltrombopag or romiplostim. at least 100 subjects will be enrolled, 50 (±10) who have received eltrombopag and 50 (±10) who have received romiplostim for at least 90 days prior to study entry.

Eligibility criteria:
inclusion criteria: * subject has been undergoing treatment for primary itp with eltrombopag or romiplostim for at least 90 days prior to the screening visit/visit 1. * subject has had a previous response (at any time) to either eltrombopag or romiplostim, defined as at least 2 platelet counts ≥50×10⁹/l. subject is willing and able to comply with all aspects of the protocol, including completing the self-administered treatment satisfaction medication questionnaire (tsqm). exclusion criteria: * subject is currently receiving chemotherapy or radiation for any form of cancer. * subject with conditions that are likely to prevent them from accurately and reliably completing study assessments, including evidence of moderate to severe dementia, and/or severe and progressive medical illness, as determined by the investigator. * any previous avatrombopag use. * previous participation in this study; a subject may not re-enroll after prior discontinuation or completion. * enrollment in another clinical study with any investigational drug or device within 30 days of baseline (or 5 half-lives, whichever is longer); however, participation in observational studies within the previous 30 days is permitted.

Keywords: itp
a study to evaluate the safety and efficacy of pac-14028 cream in adults with atopic dermatitis

Conditions: Atopic Dermatitis

Summary: this is a phase 2 study to investigate the safety and efficacy of pac-14028 cream in atopic dermatitis patients.

pac-14028 cream (0.1%, 0.3%, 1.0%) or placebo will be treated to mild to moderate atopic dermatitis patients twice daily for 8 weeks.

Eligibility criteria:
inclusion criteria: * male and female patients aged 19 - 70 years. * who was diagnosed with atopic dermatitis according to haniffin and rajka criteria. * whose affected bsa is over 5% and iga score is 2 (mild) to 3 (moderate). * who voluntarily agreed to participate in the study and signed an informed consent form. exclusion criteria: * who has skin diseases other than atopic dermatitis or scar in the affected area which can affect the study, determined by the study investigators. * who has clinically significant medical history or diseases involving liver, kidney, neurological system, psychical disorder that can affect study results. * who has used systemic steroids, antibiotics, immunosuppressants, or received photochemical therapy within 28 days before study drug administration. * who has used topical steroids, immunosuppressants or antibiotics to treat atopic dermatitis within 14 days before study drug administration. * who has used or is expected to inevitably use prohibited concomitant medications during the study. * women who is pregnant /breast-feeding, or who has childbearing potential and does not use available contraceptives. * who has dosed other study medications within 30 days before screening. * who is determined ineligible for study participation by investigators for any other reasons.
hybrid-everted versus hand-sewn or stapled esophagogastrostomy in prevention of anastomotic stricture

Conditions: Esophageal Neoplasms; Surgical Stomas

Summary: the investigators improved the hybrid everted esophagogastrostomy and expected to prevent the incidence of anastomotic stricture. the purpose of this study is to determine the clinical value of this kind of operation type, and analyzes the clinicopathological factors causing the postoperative complications.

this randomized clinical trial compared a hybrid everted esophagogastric anastomosis with conventional hand-sewn or stapled esophagogastrostomy for prevention of anastomotic stricture. the patients were completely randomized to receive either a hybrid everted esophagogastric anastomosis (he group), or the conventional hand-sewn (hs group), or a stapled (sa group) anastomosis, after the removal of esophageal tumor. the primary outcome measured the incidence of anastomotic stricture at 3 months after the operation (defined as the diameter of the anastomotic orifice \<= 0.8 cm on esophagogram), analyzed by intention-to-treat.

Eligibility criteria:
inclusion criteria: * pathologically diagnosed esophageal neoplasms * undergoing the esophagogastrostomy exclusion criteria: * the patients with previous the upper gastrointestinal tract surgery * the esophageal carcinoma patients with previous neoadjuvant chemotherapy * the esophageal carcinoma complicated other esophagogastric diseases

Keywords: esophagogastrostomy circular everted anastomosis side-side anastomosis randomized clinical trial
daratumumab in combination with lenalidomide and dexamethasone in relapsed and relapsed-refractory multiple myeloma

Conditions: Multiple Myeloma

Summary: the purpose of this study is to establish the safety profile of daratumumab when given in combination with lenalidomide and dexamethasone in participants with relapsed or relapsed and refractory multiple myeloma (mm).

the study is conducted in two parts. the dose escalation portion of the trial (part 1) participants are enrolled into cohorts at increasing dose levels of daratumumab in combination with len/dex in 28 day treatment cycles. part 2, the cohort expansion part of the trial, will further explore the maximum tolerated dose (mtd) (or the maximum tested dose) of daratumumab as determined in part 1.

Eligibility criteria:
inclusion criteria: * (part 1) have relapsed multiple myeloma after receiving a minimum of 2 and a maximum of 4 prior lines of therapy and be eligible for treatment with lenalidomide and dexamethasone (len/dex) * (part 2) have received at least 1 prior line of therapy for multiple myeloma * be older than or be 18 years of age * eastern cooperative oncology group (ecog) performance status (0-2) * provide signed informed consent after receipt of oral and written information about the study and before any study-related activity is performed exclusion criteria: * have previously received an allogenic stem cell transplant * have received autologous stem cell transplant within 12 weeks before the first infusion * have received antimyeloma treatment, radiotherapy, or any experimental drug or therapy within 2 weeks before the first infusion * have discontinued lenalidomide due to any treatment-related adverse event or be refractory to any dose of lenalidomide. refractory to lenalidomide is defined as either, participants whose disease progresses within 60 days of lenalidomide, or participants whose disease is nonresponsive while on any dose of lenalidomide. nonresponsive disease is defined as either failure to achieve at least an minimal response (mr) or development of progressive disease (pd) while on lenalidomide

Keywords: multiple myeloma daratumumab lenalidomide dexamethasone dose-escalation relapsed multiple myeloma relapsed and refractory multiple myeloma
aspirin for the treatment of nonalcoholic fatty liver disease

Conditions: Nonalcoholic Fatty Liver; Nonalcoholic Steatohepatitis

Summary: nonalcoholic fatty liver disease (nafld), defined by fatty infiltration of the liver in the absence of excess alcohol consumption, affects an estimated 30% of adults in the united states. a proportion of people with nafld will develop progressive, inflammatory nonalcoholic steatohepatitis (nash), which can progress to liver cirrhosis and liver failure. nafld is expected to be the most common indication for liver transplantation by the year 2020. we hypothesize that among adults with nafld, aspirin will reduce intrahepatic lipid content, as quantified by 1h magnetic resonance spectroscopy (1h-mrs).


Eligibility criteria:
inclusion criteria: * ages 18 to 70 years * nafld, defined by confirmed hepatic steatosis by imaging or by liver biopsy, in the absence of other causes of hepatic steatosis or significant alcohol consumption. if liver imaging or biopsy has not been performed clinically, liver ultrasound assessment will be performed as part of the screening visit. * early-stage liver fibrosis, defined as fibrosis less than or equal to fibrosis stage 3 (f3), confirmed by either (1) a recent liver biopsy or (2) a recent elastography / fibroscan study. if no recent biopsy or elastography/fibroscan have been performed, a fibroscan will be performed as part of the screening visit. exclusion criteria: * liver fibrosis stage \> 3 * current aspirin use * contraindications to aspirin use * contraindications to magnetic resonance imaging (mri) * pregnancy or desire to become pregnant * breastfeeding

Keywords: aspirin liver disease anti-inflammatory
a study to explore the role and impact of wearable smart devices in perioperative nsclc patients

Conditions: Non Small Cell Lung Cancer

Summary: the trial was designed as a single-center non-interventional prospective observational study to explore the role and impact of wearable smart devices in perioperative nsclc patients.


Eligibility criteria:
inclusion criteria: 1. participants must provide voluntary consent to participate in this research and possess the capacity to sign an informed consent form. 2. participants must be aged over 18 years. 3. participants must have undergone pulmonary resection surgery with a postoperative pathological confirmation of primary lung cancer. exclusion criteria: 1. patient refusal to participate in this research. 2. inability to wear wearable smart monitoring devices due to various reasons. 3. the pathological report suggests a non-small cell lung cancer (nsclc) exclusion. 4. history of secondary lung cancer surgery.

Keywords: non small cell lung cancer wearable devices
build-up computed assisted history taking, physical examination and diagnosis system of emergency patient through machine learning (ii)

Conditions: Internal Disease

Summary: in emergency department（ed）, physicians need to complete patient evaluation and management in a short time, which required different history taking, and physical examination skill in healthcare system. natural language processing（nlp） became easily accessible after the development of machine learning（ml）. besides, electronic medical record（emr） had been widely applied in healthcare systems. there are more and more tools try to capture certain information from the emr help clinical workers handle increasing patient data and improving patient care. however, to err is human. physicians might omit some important signs or symptoms, or forget to write it down in the record especially in a busy emergency room. it will lead to an unfavorable outcome when there were medical legal issue or national health insurance review. the condition could be limited by a emr supporting system. the quality of care will also improve. the investigators are planning to analyze emr of emergency room by nlp and machine learning. to establish the linkage between triage data, chief complaint, past history, present illness and physical examination. the investigators will try to predict the tentative diagnosis and patient disposition after the relationship being found. thereafter, the investigators could try to predict the key element of history taking and physical examination of the patient and inform the physician when the miss happened. the investigators hope the system may improve the quality of medical recording and patient care.


Eligibility criteria:
inclusion criteria: * over twenty years old * non-traumatic patient exclusion criteria: * excluding the patients for administration reasons (issuing a medical certificate) * excluding the patients for non-emergency reasons like simply acupuncture, virus screening and prescription for medication. * excluding patients who allocated to critical care station

Keywords: artificial intelligence